Teclistamab Improved All Three Outcomes in MajesTEC-9
D - All of the above is correct. In the Phase 3 MajesTEC-9 trial, teclistamab monotherapy demonstrated statistically significant improvements in progression-free survival, overall survival, AND complete response rates (which correlates with undetectable MRD) compared to standard therapies (PVd or Kd) 1.
Key Trial Results from MajesTEC-9
The MajesTEC-9 trial enrolled 593 patients with relapsed or refractory multiple myeloma who had received 1-3 prior lines of therapy, including lenalidomide and an anti-CD38 antibody. At the interim analysis with 17.3 months median follow-up 1:
Progression-Free Survival (Answer A)
- Teclistamab achieved a 71% reduction in risk of progression or death (HR 0.29; 95% CI 0.23-0.38; P<0.001)
- 18-month PFS: 69.8% with teclistamab vs. 26.9% with PVd/Kd
- This represents a dramatic and clinically meaningful improvement 1
Overall Survival (Answer B)
- Teclistamab reduced risk of death by 40% (HR 0.60; 95% CI 0.43-0.83; P=0.002)
- 18-month OS: 79.2% with teclistamab vs. 68.6% with PVd/Kd
- This OS benefit is particularly notable given the relatively early line of therapy 1
Complete Response/MRD Negativity (Answer C)
- Complete response or better: 65.9% with teclistamab vs. 16.8% with PVd/Kd (P<0.001)
- This nearly 4-fold increase in CR rates strongly correlates with deeper responses and MRD negativity
- Higher CR rates are established surrogates for MRD negativity in multiple myeloma 1
Critical Safety Considerations
While teclistamab demonstrated superior efficacy across all three outcomes, grade 3-4 infections occurred in 41.6% of patients compared to 29.0% with PVd/Kd 1. This necessitates:
- Mandatory antimicrobial prophylaxis
- Immune globulin replacement as recommended
- Close monitoring for infectious complications
Cytokine release syndrome occurred in 66% of patients but was predominantly grade 1-2, with immune effector cell-associated neurotoxicity syndrome in only 4.1% 1. Grade 5 adverse events occurred in 6.5% with teclistamab vs. 3.5% with standard therapy 1.
Clinical Context
This represents the first Phase 3 trial demonstrating that a bispecific antibody monotherapy outperforms standard combination chemotherapy in earlier-line relapsed/refractory multiple myeloma. The magnitude of benefit across all three major efficacy endpoints (PFS, OS, and depth of response) is unprecedented for this patient population 1.
The trial results support teclistamab as a preferred option for patients with 1-3 prior lines who have received lenalidomide and anti-CD38 therapy, though the infection risk requires proactive management strategies 1.